Is Nippon Shinyaku (TSE:4516) Undervalued On Its EXG 7001 Option Deal?

Nippon Shinyaku (TSE:4516) has drawn fresh investor attention after announcing an option agreement for EXG-7001, an mRNA based Duchenne muscular dystrophy therapy that could broaden its rare disease pipeline if development progresses.

See our latest analysis for Nippon Shinyaku.

Nippon Shinyaku’s latest EXG-7001 option agreement comes after a tough spell for the stock, with the share price down 21.06% over 90 days and 26.51% year to date, yet still delivering a 30.18% total shareholder return over the past year. This suggests recent weakness contrasts with stronger longer term gains.

If this rare disease announcement has you thinking more broadly about healthcare opportunities, it could be a useful moment to scan other potential candidates using our healthcare focused screener for 7 healthcare AI stocks

With Nippon Shinyaku’s share price recently under pressure despite its EXG-7001 option, the real tension now is between stepping in at today’s level or holding back for a potentially cheaper entry as the valuation stacks up next.

Preferred P/E of 9.2x: Is it justified?

Nippon Shinyaku is currently trading on a P/E of 9.2x, and at a last close of ¥4,067 the stock screens as relatively cheap compared with both peers and the broader JP market.

The P/E ratio compares the company’s share price to its earnings per share. For a pharmaceuticals business like Nippon Shinyaku it reflects what investors are willing to pay for each unit of current earnings. A lower P/E can suggest expectations for weaker profit trends, or simply that the market has been cautious despite established earnings power.

Here, the company’s P/E of 9.2x sits below the JP market average of 14x and below the estimated fair P/E of 12.4x. This points to a material valuation gap that the market could close if sentiment or earnings expectations improve. It is also well below both the peer average of 33x and the JP Pharmaceuticals industry average of 16.7x, a strong relative discount that stands out within the sector.

Explore the SWS fair ratio for Nippon Shinyaku

Result: Price-to-Earnings of 9.2x (UNDERVALUED)

However, Nippon Shinyaku’s earnings trend, with annual net income growth under pressure, and the long timelines and uncertainty around rare disease drug development could challenge this valuation gap.

Find out about the key risks to this Nippon Shinyaku narrative.

Another View: DCF Points in the Opposite Direction

While Nippon Shinyaku looks inexpensive on a 9.2x P/E, the SWS DCF model paints a different picture. With the stock at ¥4,067 versus a future cash flow value estimate of ¥2,486.85, this method suggests the shares screen as overvalued rather than cheap. Which signal would you weigh more heavily?

For a closer look at the assumptions behind this cash flow view, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Nippon Shinyaku for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 20 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of apparent value and caution around Nippon Shinyaku has you undecided, move quickly to review the numbers and form your own stance. Then weigh the balance of its 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Nippon Shinyaku?

If Nippon Shinyaku has sharpened your focus on valuation and risk, do not stop here. Use these curated ideas to broaden your watchlist before the next move.

• Target quality at a discount by reviewing companies in the 20 high quality undervalued stocks that pair established fundamentals with pricing that may not fully reflect them.
• Build stronger income potential by scanning the 43 dividend fortresses and spotting stocks that combine higher yields with a focus on resilience.
• Dial down portfolio stress by checking the 51 resilient stocks with low risk scores and concentrating on companies that score better on stability and downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com